A phase I clinical trial using Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1), in combination with Cytarabine and Mitoxantrone in 26 AML patients, found a higher frequency of PD-1+ CD4+ and CD8+ T cells in treatment-failure patients than in those achieving complete remission. The gene discussed is CD4; the disease is acute myeloid leukemia.